{"id":1021170,"date":"2026-11-16T06:45:49","date_gmt":"2026-11-16T11:45:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/"},"modified":"2026-11-16T06:45:49","modified_gmt":"2026-11-16T11:45:49","slug":"cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","title":{"rendered":"CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">Hong Kong, China, Nov.  16, 2026  (GLOBE NEWSWIRE) &#8212;  Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the \u201c<b>Company<\/b>\u201d), a leading provider of over-the-counter\u00a0(\u201cOTC\u201d) pharmaceutical cross-border e-commerce supply chain services in\u00a0Hong Kong, today announced that it received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201c<b>Nasdaq<\/b>\u201d) on November 13, 2026, confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the \u201c<b>Minimum Bid Price Requirement<\/b>\u201d) for continued listing on the Nasdaq Capital Market.<\/p>\n<p align=\"justify\">As previously announced, on January 12, 2026, Nasdaq notified the Company that the closing bid price of the Company\u2019s Class A ordinary shares had been below US$1.00 per share for 30 consecutive business days and that, as a result, the Company was not in compliance with the Minimum Bid Price Requirement. Nasdaq provided the Company with an initial compliance period of 180 calendar days, or until July 13, 2026, to regain compliance. To regain compliance, the Company was required to maintain a closing bid price of at least US$1.00 per share for a minimum of 10 consecutive business days during the compliance period. On July 14, 2026, the Company received written notice from Nasdaq granting an additional 180 calendar days, or until January 11, 2027, to regain compliance with the Minimum Bid Price Requirement.<\/p>\n<p align=\"justify\">Subsequently, on November 13, 2026, Nasdaq determined that the closing bid price of the Company\u2019s Class A ordinary shares was at least US$1.00 per share for the 14 consecutive business days from October 26 through November 12, 2026. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement, and the matter was closed.<\/p>\n<p align=\"justify\">\n        <b>About Cellyan Biotechnology Co., Ltd<\/b>\n      <\/p>\n<p align=\"justify\">Cellyan Biotechnology Co., Ltd (f.k.a. Hong Kong Pharma Digital Technology Holdings Limited) offers two main categories of services: (i) OTC pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited (\u201cJoint Cross Border\u201d), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary, V-Alliance Technology Supplies Limited.<\/p>\n<p align=\"justify\">Through its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland China. Joint Cross Border\u2019s comprehensive service offerings include pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting products with the Hong Kong Department of Health, obtaining import and export permits, storing products, packaging, and arranging logistics and end-to-end delivery services for customers.<\/p>\n<p>\n        <b>For investor and media inquiries please contact:<\/b>\u00a0<\/p>\n<p>Cellyan Biotechnology Co., Ltd<br \/>Media Contact: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7Sl5bUCp4EWTUExI-zszU-jkbsH3Y7m_0hu9GVcXvFiUwXdwVwh_THb00h5qbjmfSEnI3CFmoUhBj711V9tik5k5yCeaxs4wJXrI_jhTaJU=\" rel=\"nofollow\" target=\"_blank\">andy@cell-yan.com<\/a>\u00a0\u00a0<br \/>Investor Relations: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=k-qQ1OXfVoXl4F_sfyFabcBIDCV2u4F8yCkoMOMLASFwCNy_m36r_z9w9gPXzlyhB9x8A3B-O2B_X5kio_keQm94reCw3pTvPxolOF0-XuY=\" rel=\"nofollow\" target=\"_blank\">stella@cell-yan.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODI2MCM3OTY3NzY0IzUwMDE1NjI4MA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OWE1NjAwMTItMzlhYy00OTNhLTljNDQtNDEyMTdlMWI2ZWQ1LTUwMDE1NjI4MC0yMDI2LTExLTE2LWVu\/tiny\/Cellyan-Biotechnology-Co-Ltd.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hong Kong, China, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the \u201cCompany\u201d), a leading provider of over-the-counter\u00a0(\u201cOTC\u201d) pharmaceutical cross-border e-commerce supply chain services in\u00a0Hong Kong, today announced that it received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) on November 13, 2026, confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the \u201cMinimum Bid Price Requirement\u201d) for continued listing on the Nasdaq Capital Market. As previously announced, on January 12, 2026, Nasdaq notified the Company that the closing bid price of the Company\u2019s Class A ordinary shares had been below US$1.00 per share for 30 consecutive business days and that, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021170","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Hong Kong, China, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the \u201cCompany\u201d), a leading provider of over-the-counter\u00a0(\u201cOTC\u201d) pharmaceutical cross-border e-commerce supply chain services in\u00a0Hong Kong, today announced that it received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) on November 13, 2026, confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the \u201cMinimum Bid Price Requirement\u201d) for continued listing on the Nasdaq Capital Market. As previously announced, on January 12, 2026, Nasdaq notified the Company that the closing bid price of the Company\u2019s Class A ordinary shares had been below US$1.00 per share for 30 consecutive business days and that, &hellip; Continue reading &quot;CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T11:45:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODI2MCM3OTY3NzY0IzUwMDE1NjI4MA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT\",\"datePublished\":\"2026-11-16T11:45:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\"},\"wordCount\":430,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODI2MCM3OTY3NzY0IzUwMDE1NjI4MA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\",\"name\":\"CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODI2MCM3OTY3NzY0IzUwMDE1NjI4MA==\",\"datePublished\":\"2026-11-16T11:45:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODI2MCM3OTY3NzY0IzUwMDE1NjI4MA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODI2MCM3OTY3NzY0IzUwMDE1NjI4MA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","og_locale":"en_US","og_type":"article","og_title":"CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT - Market Newsdesk","og_description":"Hong Kong, China, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the \u201cCompany\u201d), a leading provider of over-the-counter\u00a0(\u201cOTC\u201d) pharmaceutical cross-border e-commerce supply chain services in\u00a0Hong Kong, today announced that it received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) on November 13, 2026, confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the \u201cMinimum Bid Price Requirement\u201d) for continued listing on the Nasdaq Capital Market. As previously announced, on January 12, 2026, Nasdaq notified the Company that the closing bid price of the Company\u2019s Class A ordinary shares had been below US$1.00 per share for 30 consecutive business days and that, &hellip; Continue reading \"CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T11:45:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODI2MCM3OTY3NzY0IzUwMDE1NjI4MA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT","datePublished":"2026-11-16T11:45:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/"},"wordCount":430,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODI2MCM3OTY3NzY0IzUwMDE1NjI4MA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","name":"CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODI2MCM3OTY3NzY0IzUwMDE1NjI4MA==","datePublished":"2026-11-16T11:45:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODI2MCM3OTY3NzY0IzUwMDE1NjI4MA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODI2MCM3OTY3NzY0IzUwMDE1NjI4MA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellyan-biotechnology-co-ltd-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021170"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021170\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}